CXCL13的表达促进了CAR T细胞的抗瘤活动,并增强了对PD-1阻塞的反应
Yang Zhou1,2, Wenli Zhao2, Yihan Zhu2
1Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|June 10, 2025
概括
CXCL13增强了化学抗原受体 (CAR) T细胞治疗固体瘤的作用. 在CAR T细胞中过度表达CXCL13可减少疲劳并增强抗瘤活性,特别是在免疫检查点阻塞下.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 免疫检查点阻塞 (ICB) 和仿真抗原受体 (CAR) T 细胞疗法是有效的癌症治疗方法.
- 固体瘤由于免疫抑制的微环境和T细胞枯竭而存在挑战,限制了治疗的有效性.
研究的目的:
- 研究CXCL13在增强CAR T细胞功能和对ICB的反应中的作用.
- 评估CXCL13过度表达的CAR T细胞在固体瘤中的治疗潜力.
主要方法:
- 生物信息分析在ICB反应者中发现CXCL13的升高.
- 改造小鼠和人类的CAR T细胞过度表达CXCL13.
- 评估T细胞表型,线粒体功能,增殖和体内抗瘤活性,包括与PD-1抑制的组合.
主要成果:
- 过度表达CXCL13减少了T细胞疲劳,增加了中央记忆表型,线粒体功能和增殖.
- 经CXCL13工程的CAR T细胞在体内表现出增强的抗瘤活性.
- 与PD-1抑制的联合治疗进一步改善了CAR T细胞的扩张和持久性,特别是在早期耗尽的CD8+T细胞中.
- 在体外,CXCL13给人体CAR T细胞带来了类似的好处.
结论:
- CXCL13表达改善了CAR T细胞的功能和对免疫检查点封锁的反应能力.
- 在固体瘤中,CXCL13是优化CAR T细胞治疗的有希望的策略.
- 这种方法对临床应用具有翻译相关性.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.6K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
T Cell Activation and Clonal Selection
5.9K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.9K
